LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Eli Lilly and Novo Nordisk dominate the weight-loss drug market. But pharma companies like Amgen, Viking, Zealand, Structure, AstraZeneca and Roche are racing to catch up.

Sales estimates for Eli Lilly & Company (NYSE:LLY)’s weight-loss treatment Zepbound may surpass market expectations by about 15%, according to the investment bank’s analysis, while estimates ...